Skip to main content
Clinical Trials/NCT03489512
NCT03489512WithdrawnPhase 4

Clinical Phase IV Comparison Trial for 2% Chlorhexidine Skin Asepsis +70% Alcohol Versus Aqueous Chlorhexidine (2%) for the Prevention of Catheter-related Bacteremia in Critical Patients: Preliminary Study

Instituto de Investigacion Sanitaria La Fe0 sitesStarted: October 1, 2019Last updated:
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Phase 4
Status
Withdrawn
Sponsor
Primary Endpoint
Incidence of catheter-related bacteremia

Study Overview

Brief Summary

A multicentre, open-label clinical trial of two groups comparing cutaneous asepsis with chlorhexidine gluconate at 2% + isopropyl alcohol 70% in relation to the placement of central venous catheters (Study group) with standard asepsis with aqueous chlorhexidine at 2% (Group Control). The incidence of catheter related bacteremia, the incidence of colonization of the skin and the incidence of colonization of the central venous catheter will be evaluated.

Detailed Description

A multicentre, open-label clinical trial of two groups comparing cutaneous asepsis with chlorhexidine gluconate at 2% + isopropyl alcohol 70% in relation to the placement of central venous catheters (Study group) with standard asepsis with aqueous chlorhexidine at 2% (Group Control). The incidence of catheter related bacteremia, the incidence of colonization of the skin and the incidence of colonization of the central venous catheter will be evaluated.

The patients will assigned to the treatment group depending on where and when they are treated (site A or site B) and will continue the treatment until the end (continuous design): the patients of Site A will receive the first treatment option and those of Site B will receive the second treatment option during the first 6 months. After this, a rest period of 1 month will be established, during which patients will not be recruited and any of the two cutaneous aseptic methods will be used indiscriminately, in the opinion of the responsible nursing staff. After the resting period, the treatments will be reversed during the following 6 months.

Study Design

Study Type
Interventional
Allocation
Non Randomized
Intervention Model
Parallel
Primary Purpose
Prevention
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Patients admitted to the ICU.
  • Patients with age greater than or equal to 18 years.
  • Patients who require at least one central venous catheters during 48h or more.
  • Obtaining informed consent.

Exclusion Criteria

  • Intolerance or known allergy to chlorhexidine, isopropyl alcohol or orange yellow S (E110).
  • High probability of death within 48 hours after admission.
  • Use of coated catheter.
  • Previously included in the study.

Arms & Interventions

A (Chloraprep)

Experimental

2% chlorhexidine gluconate with 70% isopropyl alcohol with a sterile 3ml single dose applicator. Use for the preparation of the skin before insertion of the central venous catheters and at each dressing change.

Intervention: A (Chloraprep) (Drug)

B (Clorhexidine 2%)

Active Comparator

2% aqueous base chlorhexidine (10 ml single dose containers). Use for the preparation of the skin before insertion of the central venous catheters and at each dressing change.

Intervention: B (Clorhexidine 2%) (Drug)

Outcomes

Primary Outcomes

Incidence of catheter-related bacteremia

Time Frame: Up to 48 hours after discharge from the ICU.

Measure the effect of cutaneous asepsis with chlorhexidine gluconate 2% + isopropyl gluconate 70% on the incidence of catheter-related bacteremia in the critical patient with respect to the control group.

Secondary Outcomes

  • Incidence of pericatheter skin colonization(Through study completion, an average of 1 year)
  • Incidence of colonization of the central venous catheter(Through study completion, an average of 1 year)

Investigators

Sponsor
Instituto de Investigacion Sanitaria La Fe
Sponsor Class
Other
Responsible Party
Sponsor

Similar Trials